Medical Xpress

FEBRUARY 21, 2023

Minority ethnicities and regions derive at least as much cardiovascular benefit from lipid-lowering therapies as majority groups despite being underrepresented in clinical trials, according to a study published today in the European Journal of Preventive Cardiology.

Cardiology 75

Cardiology Clinical Trials Clinical Trials Drugs 75

XTalks

APRIL 7, 2022

Abbott Laboratories announced on Monday that the US Food and Drug Administration (FDA) approved its Aveir™ single-chamber (VR) leadless pacemaker system. XTALKS WEBINAR: Cardiac Safety Solutions in Decentralized Clinical Trials (DCT). Live and On-Demand: Tuesday, May 24, 2022, at 1pm EDT (10am PDT).

FDA Approval 105

FDA Approval Clinical Trials Clinical Trials Cardiology 105

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

XTalks

JANUARY 3, 2025

Ionis Pharmaceuticals recently announced that its drug, Tryngolza (olezarsen), has been approved as an adjunct to diet for the reduction of triglyceride levels in FCS patients, who have long faced a condition with no existing pharmacological solutions. In the Balance study, patients who received the drug showed a 42.5

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

XTalks

JULY 7, 2023

a Canadian biopharmaceutical firm specializing in cardiovascular therapies, recently reported positive results from a Phase III clinical trial of its leading candidate, etripamil nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT). One such drug is Adenosine, which was initially approved by the FDA in 1989.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

XTalks

DECEMBER 26, 2024

Menarini Group has announced positive topline data from the Phase III BROADWAY and TANDEM clinical trials, evaluating obicetrapib and the fixed-dose combination of obicetrapib with ezetimibe.

Trials 52

Trials Life Science Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 30, 2021

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC).

Drugs 52

Drugs Cardiology Clinical Trials Clinical Trials 52

Velocity Clinical Research

NOVEMBER 21, 2023

“I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. The site has 2 full-time investigators and cooperates closely with specialists for internal medicine, orthopedics, neurology, and cardiology.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

pharmaphorum

JUNE 17, 2022

The licensing deal took place as AZ was trimming down its pipeline to focus its R&D activities on the core areas of cardiology, diabetes and neurology, and recovering from a series of patent expiries that hit its revenues. Since then it has bounced back dramatically, thanks to fast-growing drugs for cancer and heart disease.

Licensing 81

Licensing Licensing Cardiology Antibody 81

Scienmag

OCTOBER 19, 2020

Randomized clinical trial finds no mortality risk or benefit associated with drug-coated devices in the treatment of peripheral artery disease NEW YORK – October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) (..)

Trials 51

Trials Clinical Trials Clinical Trials Drugs 51

pharmaphorum

MAY 18, 2021

Treatments are limited for this form of atherosclerosis, with options including cholesterol-lowering drugs and extra medications for fluid retention or heart failure. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. As a result, Sponsors and CROs can benefit from simplified access to international clinical research capabilities. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Scienmag

OCTOBER 21, 2020

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73

Drugs Research Clinical Trials Clinical Trials 73

The Pharma Data

MARCH 22, 2022

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease. senior vice president, head of cardiovascular development and global drug development at Bristol Myers Squibb. “We

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

Scienmag

NOVEMBER 16, 2020

ET, Monday, November 16, 2020, Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of […].

Trials 41

Trials FDA Approval Clinical Trials Clinical Trials 41

pharmaphorum

OCTOBER 8, 2020

UK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, which could be used as a treatment for atrial fibrillation without the need for medication. months follow up. months follow up.

Trials 52

Trials Clinical Trials Clinical Trials Clinical Development 52

Delveinsight

JULY 22, 2021

The decision gave Bayer complete control of BlueRock’s cell therapy pipeline, headed by DA01 and spanning various diseases in the neurology , cardiology , and immunology categories. It looks to carry on with a new class of oral, once-daily, small molecule drugs called Controlled Metabolic Accelerators (CMAs).

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

The Pharma Data

JUNE 28, 2021

Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. Food and Drug Administration (FDA) in January 2021 and was recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) in the EU in May 2021.

Cardiology 52

Cardiology Production Development Medicine 52

Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research. and Europe.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

The Pharma Data

FEBRUARY 21, 2022

We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Strong pipeline with robust late-stage development program and broad potential across indications.

Radiology 52

Radiology Cardiology Development Production 52

Trialfacts

APRIL 2, 2024

Upon entering the treatment phase, there will be a 16-week ramp-up period during which the amount of study drug is gradually increased to aid the body in acclimating to the treatment. CORE Research Group CORE Research Group is owned and run by a consultant cardiologist and has successfully run clinical trials for almost 30 years.

Research 52

Research Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

Pharma Marketing Network

FEBRUARY 27, 2025

Scientific Articles & Whitepapers HCPs rely on credible, research-backed content to stay informed about new treatments, drug efficacy, and emerging medical trends. Pharma brands can develop: Whitepapers on clinical trials showcasing drug effectiveness. Chatbots answering FAQs on drug safety and usage.

Branding 52

Branding Marketing Compliance Pharma Companies 52

Scienmag

NOVEMBER 16, 2020

SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria; SOLOIST shows an SGLT2 inhibitor is safe to start in patients hospitalized with heart failure Boston, MA — Less than a decade ago, the Food and Drug Administration approved […].

Trials 65

Trials Drugs Clinical Trials Clinical Trials 65

Delveinsight

AUGUST 3, 2021

The Late-Breaking Trial Data at TVT Prove Sustained Safety and Performance of WATCHMAN FLX Left Atrial Appendage Closure Device. According to analyst views, interventional cardiology sales grew at around 7% in the first quarter of 2021 versus 2020 with structural heart franchise WATCHMAN, ACURATE neo2, and SENTINEL.

FDA Approval 98

FDA Approval Marketing Cardiology Production 98

The Pharma Data

AUGUST 30, 2021

FoCus is a pivotal, Phase III, randomised, rater-blinded, multi-centre clinical trial designed to evaluate the efficacy and safety of ALXN1840 versus SoC in patients with Wilson disease aged 12 years and older. ALXN1840 has been granted Orphan Drug Designation in the US and EU for Wilson disease. Source link: [link].

Trials 52

Trials Genetics Cardiology Medicine 52

The Pharma Data

NOVEMBER 2, 2020

Food and Drug Administration (FDA) approval of Bronchitol (mannitol) inhalation powder. market and congratulate all Chiesi team members and partners who supported the clinical process.”. You are encouraged to report negative side effects of prescription drugs to the FDA. 02, 2020 (GLOBE NEWSWIRE) — Chiesi USA, Inc.,

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

Scienmag

FEBRUARY 16, 2021

Food and Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) will participate in this “collaborative community” A medical “collaboratory” is a forum in which multidisciplinary private and public sector members work together on medical […].

Radiology 48

Radiology Drugs Clinical Trials Clinical Trials 48

Scienmag

MAY 16, 2021

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai.

Antibody 45

Antibody Genotype Drugs Clinical Trials 45

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

Scienmag

NOVEMBER 15, 2020

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites (..)

Antibody 40

Antibody Medicine Drugs Clinical Trials 40

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

XTalks

JULY 10, 2023

We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

The Pharma Data

OCTOBER 29, 2020

We remain focused on continuing to serve patients, protecting the health and safety of our employees and the communities in which we live and work, and supporting patients in clinical trials. The COVID-19 impact has varied by study and program, but there has been little timing impact on fully-enrolled trials.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

The Pharma Data

JANUARY 12, 2021

Dosing is underway in Phase 3 trials of ULTOMIRIS in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ALXN2060 (AG10) in ATTR cardiomyopathy in Japan , CAEL -101 in AL amyloidosis and ALXN2040 in paroxysmal nocturnal hemoglobinuria (PNH) patients with extravascular hemolysis (EVH).

Containment 52

Containment Development Sales Production 52

XTalks

FEBRUARY 6, 2024

Yet, despite the overwhelming evidence linking CKD with this heightened cardiovascular risk, CKD patients are often underrepresented or outright excluded from cardiovascular clinical trials. Vice President of the Medical Department and Cardiology therapeutic lead, and Heather Lohr, Sr. Director of Clinical Trial Management.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

XTalks

AUGUST 4, 2022

Cardiovascular clinical trials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinical trials. The Diversity of the US Population.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52